| Literature DB >> 29776936 |
Meijun Si1, Huiqun Li1, Yanru Chen1, Hui Peng1.
Abstract
Ethambutol (EMB) and isoniazid (INH) are the first-line antituberculosis (anti-TB) drugs. However, their neurotoxicity could cause adverse effect and the patients with end-stage renal disease are especially vulnerable due to the reduction in renal drug clearance. Here, we report a 36-year-old man receiving peritoneal dialysis developed progressive paralysis in lower extremities, vision loss and hoarseness 4 months after anti-TB treatment with INH, EMB and rifapentine because of concomitant pulmonary tuberculosis. A diagnosis of EMB/INH-induced peripheral neuropathy, retrobulbar neuritis and laryngoparalysis was made. The patient's neuropathy gradually improved 2 years after discontinuation of EMB/INH. Since EMB and INH may cause simultaneously severe and complex multineuropathy in dialysis patients, their adverse effects should be closely supervised in dialysis patients. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.Entities:
Keywords: dialysis; peripheral nerve disease; tuberculosis; unwanted effects / adverse reactions
Mesh:
Substances:
Year: 2018 PMID: 29776936 PMCID: PMC5965810 DOI: 10.1136/bcr-2017-223187
Source DB: PubMed Journal: BMJ Case Rep ISSN: 1757-790X